Vera Therapeutics Inc (VERA)
41.38
-0.56
(-1.34%)
USD |
NASDAQ |
May 17, 16:00
41.38
0.00 (0.00%)
After-Hours: 20:00
Vera Therapeutics Enterprise Value: 1.910B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.910B |
| May 16, 2024 | 1.941B |
| May 15, 2024 | 1.982B |
| May 14, 2024 | 1.882B |
| May 13, 2024 | 1.875B |
| May 10, 2024 | 1.907B |
| May 09, 2024 | 1.962B |
| May 08, 2024 | 2.105B |
| May 07, 2024 | 2.108B |
| May 06, 2024 | 2.137B |
| May 03, 2024 | 2.023B |
| May 02, 2024 | 2.015B |
| May 01, 2024 | 1.951B |
| April 30, 2024 | 1.798B |
| April 29, 2024 | 1.900B |
| April 26, 2024 | 1.806B |
| April 25, 2024 | 1.753B |
| April 24, 2024 | 1.822B |
| April 23, 2024 | 1.799B |
| April 22, 2024 | 1.777B |
| April 19, 2024 | 1.716B |
| April 18, 2024 | 1.796B |
| April 17, 2024 | 1.825B |
| April 16, 2024 | 1.965B |
| April 15, 2024 | 2.180B |
| Date | Value |
|---|---|
| April 12, 2024 | 2.259B |
| April 11, 2024 | 2.305B |
| April 10, 2024 | 1.913B |
| April 09, 2024 | 1.711B |
| April 08, 2024 | 1.750B |
| April 05, 2024 | 1.690B |
| April 04, 2024 | 1.684B |
| April 03, 2024 | 1.803B |
| April 02, 2024 | 1.871B |
| April 01, 2024 | 1.953B |
| March 28, 2024 | 2.237B |
| March 27, 2024 | 2.276B |
| March 26, 2024 | 2.153B |
| March 25, 2024 | 2.131B |
| March 22, 2024 | 2.122B |
| March 21, 2024 | 2.224B |
| March 20, 2024 | 2.357B |
| March 19, 2024 | 2.253B |
| March 18, 2024 | 2.147B |
| March 15, 2024 | 2.212B |
| March 14, 2024 | 2.225B |
| March 13, 2024 | 2.318B |
| March 12, 2024 | 2.262B |
| March 11, 2024 | 2.208B |
| March 08, 2024 | 2.268B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
60.56M
Minimum
Jan 09 2023
2.528B
Maximum
Mar 01 2024
545.95M
Average
387.78M
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 104.72B |
| Alpine Immune Sciences Inc | 4.151B |
| Fate Therapeutics Inc | 60.40M |
| Mersana Therapeutics Inc | 176.21M |
| Equillium Inc | 22.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.38M |
| Total Expenses (Quarterly) | 31.11M |
| EPS Diluted (Quarterly) | -0.56 |
| Earnings Yield | -4.95% |